Pro-permeability Factors in Diabetic Macular Edema; The Diabetic Macular Edema Treated with Ozurdex Trial

Peter A Campochiaro, Gulnar Hafiz, Tahreem A. Mir, Adrienne Scott, Ingrid E Zimmer Galler, Syed M. Shah, Adam Wenick, Christopher J. Brady, Ian Han, Lingmin He, Roomasa Channa, David Poon, Catherine Meyerle, Mary Beth Aronow, Akrit Sodhi, James Handa, Saleema Kherani, Yong Han, Raafay Sophie, Guohua Wang & 1 others Jiang Qian

Research output: Contribution to journalArticle

Abstract

Purpose The Diabetic Macular Edema Treated with Ozurdex (DMEO) Trial measured aqueous pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after injection of dexamethasone implant or vascular endothelial growth factor (VEGF)-neutralizing protein and correlated changes in levels with changes in excess foveal thickness (EFT) to identify potential PPFs contributing to DME. Design Prospective, randomized crossover clinical trial. Methods Twenty DME patients randomized to dexamethasone implant or VEGF-neutralizing protein had aqueous taps and spectral-domain optical coherence tomography (SDOCT) at baseline and every 4 weeks for 28 weeks. Aqueous levels of 55 vasoactive proteins were measured with protein array. Crossover at week 16 provided changes in protein levels after each intervention in all 20 patients. Results After dexamethasone implant there was significant correlation between changes in levels of 13 vasoactive proteins with changes in EFT, including 3 known PPFs: angiopoietin-2 (r = 0.40, P =.001), hepatocyte growth factor (HGF; r = 0.31, P =.02), and endocrine gland-VEGF (EG-VEGF, r = 0.43, P

Original languageEnglish (US)
Pages (from-to)13-23
Number of pages11
JournalAmerican Journal of Ophthalmology
Volume168
DOIs
StatePublished - Aug 1 2016

Fingerprint

Macular Edema
Permeability
Vascular Endothelial Growth Factor A
Dexamethasone
Proteins
Angiopoietin-2
Endocrine Glands
Protein Array Analysis
Hepatocyte Growth Factor
Optical Coherence Tomography
Cross-Over Studies
Randomized Controlled Trials
Injections

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Pro-permeability Factors in Diabetic Macular Edema; The Diabetic Macular Edema Treated with Ozurdex Trial. / Campochiaro, Peter A; Hafiz, Gulnar; Mir, Tahreem A.; Scott, Adrienne; Zimmer Galler, Ingrid E; Shah, Syed M.; Wenick, Adam; Brady, Christopher J.; Han, Ian; He, Lingmin; Channa, Roomasa; Poon, David; Meyerle, Catherine; Aronow, Mary Beth; Sodhi, Akrit; Handa, James; Kherani, Saleema; Han, Yong; Sophie, Raafay; Wang, Guohua; Qian, Jiang.

In: American Journal of Ophthalmology, Vol. 168, 01.08.2016, p. 13-23.

Research output: Contribution to journalArticle

Campochiaro, Peter A ; Hafiz, Gulnar ; Mir, Tahreem A. ; Scott, Adrienne ; Zimmer Galler, Ingrid E ; Shah, Syed M. ; Wenick, Adam ; Brady, Christopher J. ; Han, Ian ; He, Lingmin ; Channa, Roomasa ; Poon, David ; Meyerle, Catherine ; Aronow, Mary Beth ; Sodhi, Akrit ; Handa, James ; Kherani, Saleema ; Han, Yong ; Sophie, Raafay ; Wang, Guohua ; Qian, Jiang. / Pro-permeability Factors in Diabetic Macular Edema; The Diabetic Macular Edema Treated with Ozurdex Trial. In: American Journal of Ophthalmology. 2016 ; Vol. 168. pp. 13-23.
@article{32427332d40c44c79d6a9c617d5660b9,
title = "Pro-permeability Factors in Diabetic Macular Edema; The Diabetic Macular Edema Treated with Ozurdex Trial",
abstract = "Purpose The Diabetic Macular Edema Treated with Ozurdex (DMEO) Trial measured aqueous pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after injection of dexamethasone implant or vascular endothelial growth factor (VEGF)-neutralizing protein and correlated changes in levels with changes in excess foveal thickness (EFT) to identify potential PPFs contributing to DME. Design Prospective, randomized crossover clinical trial. Methods Twenty DME patients randomized to dexamethasone implant or VEGF-neutralizing protein had aqueous taps and spectral-domain optical coherence tomography (SDOCT) at baseline and every 4 weeks for 28 weeks. Aqueous levels of 55 vasoactive proteins were measured with protein array. Crossover at week 16 provided changes in protein levels after each intervention in all 20 patients. Results After dexamethasone implant there was significant correlation between changes in levels of 13 vasoactive proteins with changes in EFT, including 3 known PPFs: angiopoietin-2 (r = 0.40, P =.001), hepatocyte growth factor (HGF; r = 0.31, P =.02), and endocrine gland-VEGF (EG-VEGF, r = 0.43, P",
author = "Campochiaro, {Peter A} and Gulnar Hafiz and Mir, {Tahreem A.} and Adrienne Scott and {Zimmer Galler}, {Ingrid E} and Shah, {Syed M.} and Adam Wenick and Brady, {Christopher J.} and Ian Han and Lingmin He and Roomasa Channa and David Poon and Catherine Meyerle and Aronow, {Mary Beth} and Akrit Sodhi and James Handa and Saleema Kherani and Yong Han and Raafay Sophie and Guohua Wang and Jiang Qian",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.ajo.2016.04.017",
language = "English (US)",
volume = "168",
pages = "13--23",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Pro-permeability Factors in Diabetic Macular Edema; The Diabetic Macular Edema Treated with Ozurdex Trial

AU - Campochiaro, Peter A

AU - Hafiz, Gulnar

AU - Mir, Tahreem A.

AU - Scott, Adrienne

AU - Zimmer Galler, Ingrid E

AU - Shah, Syed M.

AU - Wenick, Adam

AU - Brady, Christopher J.

AU - Han, Ian

AU - He, Lingmin

AU - Channa, Roomasa

AU - Poon, David

AU - Meyerle, Catherine

AU - Aronow, Mary Beth

AU - Sodhi, Akrit

AU - Handa, James

AU - Kherani, Saleema

AU - Han, Yong

AU - Sophie, Raafay

AU - Wang, Guohua

AU - Qian, Jiang

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Purpose The Diabetic Macular Edema Treated with Ozurdex (DMEO) Trial measured aqueous pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after injection of dexamethasone implant or vascular endothelial growth factor (VEGF)-neutralizing protein and correlated changes in levels with changes in excess foveal thickness (EFT) to identify potential PPFs contributing to DME. Design Prospective, randomized crossover clinical trial. Methods Twenty DME patients randomized to dexamethasone implant or VEGF-neutralizing protein had aqueous taps and spectral-domain optical coherence tomography (SDOCT) at baseline and every 4 weeks for 28 weeks. Aqueous levels of 55 vasoactive proteins were measured with protein array. Crossover at week 16 provided changes in protein levels after each intervention in all 20 patients. Results After dexamethasone implant there was significant correlation between changes in levels of 13 vasoactive proteins with changes in EFT, including 3 known PPFs: angiopoietin-2 (r = 0.40, P =.001), hepatocyte growth factor (HGF; r = 0.31, P =.02), and endocrine gland-VEGF (EG-VEGF, r = 0.43, P

AB - Purpose The Diabetic Macular Edema Treated with Ozurdex (DMEO) Trial measured aqueous pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after injection of dexamethasone implant or vascular endothelial growth factor (VEGF)-neutralizing protein and correlated changes in levels with changes in excess foveal thickness (EFT) to identify potential PPFs contributing to DME. Design Prospective, randomized crossover clinical trial. Methods Twenty DME patients randomized to dexamethasone implant or VEGF-neutralizing protein had aqueous taps and spectral-domain optical coherence tomography (SDOCT) at baseline and every 4 weeks for 28 weeks. Aqueous levels of 55 vasoactive proteins were measured with protein array. Crossover at week 16 provided changes in protein levels after each intervention in all 20 patients. Results After dexamethasone implant there was significant correlation between changes in levels of 13 vasoactive proteins with changes in EFT, including 3 known PPFs: angiopoietin-2 (r = 0.40, P =.001), hepatocyte growth factor (HGF; r = 0.31, P =.02), and endocrine gland-VEGF (EG-VEGF, r = 0.43, P

UR - http://www.scopus.com/inward/record.url?scp=84971351125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971351125&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2016.04.017

DO - 10.1016/j.ajo.2016.04.017

M3 - Article

VL - 168

SP - 13

EP - 23

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

ER -